Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention

Xiao Juan Zhang, Tong Wen Sun, Quan Cheng Kan, Hai Mu Yao, You Dong Wan, Rui Yao, Fangxia Guan, Chang Qing Guo, Shu Guang Zhang, Wen Ju Sun, Le Xin Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to investigate the associated between serum total bilirubin (STB) levels and long-term outcomes in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods: A total of 1,273 consecutive patients were enrolled. Patients were grouped according to their baseline STB levels: Group 1 (STB < 3.4 μmol/L), Group 2 (3.4 μmol/L ≤ STB ≤ 10.3 μmol/L), Group 3 (10.3 μmol/L < STB ≤ 17.1 μmol/L), and Group 4 (STB > 17.1 μmol/L) and the rate of major adverse cardiovascular events (MACE) was determined Results: A total of 1,152 patients were successfully followed up (90.5%) for a mean period of 30 ± 5 months, including 187 patients experiencing a major adverse cardiovascular event (MACE: death from any cause, myocardial infarction, repeat revascularization or readmission). The MACE rate in Groups 3 and 4 was lower than in Groups 1 and 2 (P < 0.01). After adjusted the confounding factors with Cox regression analysis, the MACE rates in Groups 2-4 were still lower than in Group 1 (Group 2, RR=0.293, 95% CI 0.167-0.517, P<0.01; Group 3, RR=0.142, 95% CI 0.065-0.312, P<0.01; Group 4, RR=0.134, 95% CI 0.071-0.252, P<0.01). The cumulative survival rates of Groups 3 and 4 were higher than that of Groups 1and 2 (P<0.01). Conclusions: High STB concentration is associated with lower MACE in patients with ACS after PCI.

Original languageEnglish (US)
Pages (from-to)E345-E351
JournalClinical and Investigative Medicine
Volume37
Issue number5
StatePublished - 2014
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Bilirubin
Serum
Acute Coronary Syndrome
Cause of Death
Survival Rate
Myocardial Infarction
Regression Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zhang, X. J., Sun, T. W., Kan, Q. C., Yao, H. M., Wan, Y. D., Yao, R., ... Wang, L. X. (2014). Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention. Clinical and Investigative Medicine, 37(5), E345-E351.

Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention. / Zhang, Xiao Juan; Sun, Tong Wen; Kan, Quan Cheng; Yao, Hai Mu; Wan, You Dong; Yao, Rui; Guan, Fangxia; Guo, Chang Qing; Zhang, Shu Guang; Sun, Wen Ju; Wang, Le Xin.

In: Clinical and Investigative Medicine, Vol. 37, No. 5, 2014, p. E345-E351.

Research output: Contribution to journalArticle

Zhang, XJ, Sun, TW, Kan, QC, Yao, HM, Wan, YD, Yao, R, Guan, F, Guo, CQ, Zhang, SG, Sun, WJ & Wang, LX 2014, 'Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention', Clinical and Investigative Medicine, vol. 37, no. 5, pp. E345-E351.
Zhang, Xiao Juan ; Sun, Tong Wen ; Kan, Quan Cheng ; Yao, Hai Mu ; Wan, You Dong ; Yao, Rui ; Guan, Fangxia ; Guo, Chang Qing ; Zhang, Shu Guang ; Sun, Wen Ju ; Wang, Le Xin. / Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention. In: Clinical and Investigative Medicine. 2014 ; Vol. 37, No. 5. pp. E345-E351.
@article{11c3ee5d629a4d0cae14e52ed2855a28,
title = "Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention",
abstract = "Purpose: The purpose of this study was to investigate the associated between serum total bilirubin (STB) levels and long-term outcomes in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods: A total of 1,273 consecutive patients were enrolled. Patients were grouped according to their baseline STB levels: Group 1 (STB < 3.4 μmol/L), Group 2 (3.4 μmol/L ≤ STB ≤ 10.3 μmol/L), Group 3 (10.3 μmol/L < STB ≤ 17.1 μmol/L), and Group 4 (STB > 17.1 μmol/L) and the rate of major adverse cardiovascular events (MACE) was determined Results: A total of 1,152 patients were successfully followed up (90.5{\%}) for a mean period of 30 ± 5 months, including 187 patients experiencing a major adverse cardiovascular event (MACE: death from any cause, myocardial infarction, repeat revascularization or readmission). The MACE rate in Groups 3 and 4 was lower than in Groups 1 and 2 (P < 0.01). After adjusted the confounding factors with Cox regression analysis, the MACE rates in Groups 2-4 were still lower than in Group 1 (Group 2, RR=0.293, 95{\%} CI 0.167-0.517, P<0.01; Group 3, RR=0.142, 95{\%} CI 0.065-0.312, P<0.01; Group 4, RR=0.134, 95{\%} CI 0.071-0.252, P<0.01). The cumulative survival rates of Groups 3 and 4 were higher than that of Groups 1and 2 (P<0.01). Conclusions: High STB concentration is associated with lower MACE in patients with ACS after PCI.",
author = "Zhang, {Xiao Juan} and Sun, {Tong Wen} and Kan, {Quan Cheng} and Yao, {Hai Mu} and Wan, {You Dong} and Rui Yao and Fangxia Guan and Guo, {Chang Qing} and Zhang, {Shu Guang} and Sun, {Wen Ju} and Wang, {Le Xin}",
year = "2014",
language = "English (US)",
volume = "37",
pages = "E345--E351",
journal = "Clinical and Investigative Medicine",
issn = "0147-958X",
publisher = "The Canadian Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Serum total bilirubin and long-term outcome in patients undergoing percutaneous coronary intervention

AU - Zhang, Xiao Juan

AU - Sun, Tong Wen

AU - Kan, Quan Cheng

AU - Yao, Hai Mu

AU - Wan, You Dong

AU - Yao, Rui

AU - Guan, Fangxia

AU - Guo, Chang Qing

AU - Zhang, Shu Guang

AU - Sun, Wen Ju

AU - Wang, Le Xin

PY - 2014

Y1 - 2014

N2 - Purpose: The purpose of this study was to investigate the associated between serum total bilirubin (STB) levels and long-term outcomes in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods: A total of 1,273 consecutive patients were enrolled. Patients were grouped according to their baseline STB levels: Group 1 (STB < 3.4 μmol/L), Group 2 (3.4 μmol/L ≤ STB ≤ 10.3 μmol/L), Group 3 (10.3 μmol/L < STB ≤ 17.1 μmol/L), and Group 4 (STB > 17.1 μmol/L) and the rate of major adverse cardiovascular events (MACE) was determined Results: A total of 1,152 patients were successfully followed up (90.5%) for a mean period of 30 ± 5 months, including 187 patients experiencing a major adverse cardiovascular event (MACE: death from any cause, myocardial infarction, repeat revascularization or readmission). The MACE rate in Groups 3 and 4 was lower than in Groups 1 and 2 (P < 0.01). After adjusted the confounding factors with Cox regression analysis, the MACE rates in Groups 2-4 were still lower than in Group 1 (Group 2, RR=0.293, 95% CI 0.167-0.517, P<0.01; Group 3, RR=0.142, 95% CI 0.065-0.312, P<0.01; Group 4, RR=0.134, 95% CI 0.071-0.252, P<0.01). The cumulative survival rates of Groups 3 and 4 were higher than that of Groups 1and 2 (P<0.01). Conclusions: High STB concentration is associated with lower MACE in patients with ACS after PCI.

AB - Purpose: The purpose of this study was to investigate the associated between serum total bilirubin (STB) levels and long-term outcomes in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods: A total of 1,273 consecutive patients were enrolled. Patients were grouped according to their baseline STB levels: Group 1 (STB < 3.4 μmol/L), Group 2 (3.4 μmol/L ≤ STB ≤ 10.3 μmol/L), Group 3 (10.3 μmol/L < STB ≤ 17.1 μmol/L), and Group 4 (STB > 17.1 μmol/L) and the rate of major adverse cardiovascular events (MACE) was determined Results: A total of 1,152 patients were successfully followed up (90.5%) for a mean period of 30 ± 5 months, including 187 patients experiencing a major adverse cardiovascular event (MACE: death from any cause, myocardial infarction, repeat revascularization or readmission). The MACE rate in Groups 3 and 4 was lower than in Groups 1 and 2 (P < 0.01). After adjusted the confounding factors with Cox regression analysis, the MACE rates in Groups 2-4 were still lower than in Group 1 (Group 2, RR=0.293, 95% CI 0.167-0.517, P<0.01; Group 3, RR=0.142, 95% CI 0.065-0.312, P<0.01; Group 4, RR=0.134, 95% CI 0.071-0.252, P<0.01). The cumulative survival rates of Groups 3 and 4 were higher than that of Groups 1and 2 (P<0.01). Conclusions: High STB concentration is associated with lower MACE in patients with ACS after PCI.

UR - http://www.scopus.com/inward/record.url?scp=84930511602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930511602&partnerID=8YFLogxK

M3 - Article

C2 - 25282141

AN - SCOPUS:84930511602

VL - 37

SP - E345-E351

JO - Clinical and Investigative Medicine

JF - Clinical and Investigative Medicine

SN - 0147-958X

IS - 5

ER -